COST-EFFECTIVENESS OF LENALIDOMIDE/DEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS WITH A PRIOR THALIMODMIDE THERAPY

被引：0

作者：

Schey, S. ^{[1
]}

Stern, S. ^{[2
]}

Dhanasiri, S. ^{[3
]}

Brown, R. ^{[2
]}

机构：

[1] Kings Coll Hosp London, London, England

[2] United BioSource Corp, Bethesda, MD USA

[3] Celgene Ltd, Uxbridge, Middx, England

来源：

HAEMATOLOGICA | 2012年 / 97卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1087

引用

页码：443 / 443

页数：1

共 50 条

[21] Cost-Effectiveness of Post-Autotransplant Lenalidomide in Persons with Multiple Myeloma
Marchetti, Monia
Gale, Robert Peter
Barosi, Giovanni
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2021, 13
[22] COST-EFFECTIVENESS ANALYSIS OF IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE VERSUS DARATUMUMAB PLUS LENALIDOMIDEDEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS RECEIVED MORE THAN ONE PRIOR TREATMENT IN CHINA
Zhao, X.
Feng, Y.
Zhu, L.
Liu, J.
VALUE IN HEALTH, 2020, 23 : S442 - S442
[23] Lenalidomide Plus Bortezomib and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma: Results from a Canadian Cost-Effectiveness Analysis
Sebag, Michael
Stakiw, Julie
Stephens, Thomas J.
Padhiar, Amie
Kim, Tony
Shum, Jane
Dhanasiri, Sujith
Trudel, Suzanne
BLOOD, 2019, 134
[24] COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN PORTUGAL
Paquete, A. T.
Gouveia, M.
Guerreiro, R.
Anjo, J.
Magalhaes, C.
Borges, M.
VALUE IN HEALTH, 2019, 22 : S448 - S448
[25] Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China
Lu, Jin
Chen, Wendong
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (12) : 979 - 992
[26] Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux
Usmani, Saad Z.
Dimopoulos, Meletios A.
Belch, Andrew
White, Darrell
Benboubker, Lofti
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Khokhar, Nushmia Z.
Guckert, Mary
Wu, Kaida
Qin, Xiang
Casneuf, Tineke
Chiu, Christopher
Sasser, A. Kate
San-Miguel, Jesus
BLOOD, 2016, 128 (22)
[27] Bortezomib-Based Therapy Following Prior Lenalidomide plus Dexamethasone in Relapsed Multiple Myeloma
Trieu, Y.
Xu, W.
Masih-Khan, E.
Dean, S.
Trudel, S.
Kukreti, V.
Anglin, P.
Chen, C.
Mikhael, J.
Reece, D.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S53 - S54
[28] COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) AND DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD) VERSUS STANDARD OF CARE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Pelligra, C.
Guo, S.
Parikh, K.
Zhang, S.
Krotneva, M.
Onyekwere, U.
Clancy, Z.
VALUE IN HEALTH, 2018, 21 : S254 - S254
[29] Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma
Richter, Joshua R.
Bilotti, Elizabeth
McBride, Laura
Schmidt, Linda
Gao, Zhijie
Tufail, Madiha
Anand, Palka
McNeill, Ann
Bednarz, Urszula
Graef, Thorsten
Vesole, David H.
Siegel, David S.
BLOOD, 2011, 118 (21) : 1706 - 1706
[30] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Richardson, Paul G.
Weller, Edie
Lonial, Sagar
Jakubowiak, Andrzej J.
Jagannath, Sundar
Raje, Noopur S.
Avigan, David E.
Xie, Wanling
Ghobrial, Irene M.
Schlossman, Robert L.
Mazumder, Amitabha
Munshi, Nikhil C.
Vesole, David H.
Joyce, Robin
Kaufman, Jonathan L.
Doss, Deborah
Warren, Diane L.
Lunde, Laura E.
Kaster, Sarah
DeLaney, Carol
Hideshima, Teru
Mitsiades, Constantine S.
Knight, Robert
Esseltine, Dixie-Lee
Anderson, Kenneth C.
BLOOD, 2010, 116 (05) : 679 - 686

← 1 2 3 4 5 →